MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments

DUBAI, United Arab Emirates - Monday, 31. August 2026


    David Ogg appointed Vice Chairman and Brian Andreyko named CEO

 

(BUSINESS WIRE)--MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform.

David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also included senior roles at Credit Suisse, Lehman Brothers, HSBC and Dresdner Kleinwort Benson, as well as work with Bloomberg and Citibank on institutional FX trading solutions. He has been inducted into the Profit & Loss Hall of Fame.

Commenting on his appointment, David Ogg, Vice Chairman of MEX Exchange, said: “Institutional FX has evolved considerably over the past several decades, but there remains significant scope for innovation in how liquidity is accessed, matched and executed. At MEX Exchange, our focus is on combining deep market expertise with advanced technology to build an institutional trading venue that addresses the evolving requirements of market participants globally. I look forward to supporting the company’s strategic direction in my new role as Vice Chairman.”

Brian Andreyko brings over 30 years of experience in financial technology and institutional markets, with a track record of building, scaling and leading electronic trading businesses. He previously served as Chief Operating Officer and Chief of Staff at Currenex, and as Executive Vice President and Head of EBS at ICAP. He also served as CEO of MakoFX/Liquidity Pool and Chief Business Officer at TradAir, both of which were subsequently acquired.

Brian Andreyko, CEO of MEX Exchange, said: “MEX Exchange has a clear opportunity to bring a differentiated proposition to the institutional trading market. My priority as CEO will be to translate our technology and market expertise into a scalable platform that delivers speed, efficiency and a strong execution experience bringing together Emerging Market and Global participants. I look forward to working closely with David and the wider team as we move into the next stage of the company’s growth.”

The appointments form part of MEX Exchange’s continued investment in its leadership and institutional capabilities, supporting its ambition to expand its presence across global electronic trading markets.

ABOUT MULTIBANK GROUP

MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives, serving over 2 million clients across 100 countries, and boasts a daily trading volume that exceeds $35 billion. Renowned for its innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group offers an array of brokerage services and asset management solutions. It is regulated across five continents by 18+ of the most reputable financial authorities globally. The group’s award-winning trading platforms offer up to 1000:1 leverage on a diverse range of products, including Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 financial awards recognizing its trading excellence and regulatory compliance. For more information, visit MultiBank Group’s www.multibankgroup.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831401493/en/

Permalink
https://www.aetoswire.com/en/news/3108202656968

Contacts

Nikolas Neofytou
nikolas.neofytou@multibankfx.com

Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis

 GRONINGEN, Netherlands - 

(BUSINESS WIRE)--QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectrometry (ICP-MS) systems to be housed in its Netherlands laboratories. The new instruments will replace two Agilent 7700 ICP-MS systems currently operating within the bioanalysis department. The NexION® 2200 platform was selected to support robust trace-element analysis, effective management of analytical interferences, reliable performance with challenging sample matrices, and efficient laboratory operations.

The investment is part of a broader upgrade and renewal program focused on maintaining a modern, reliable, and sustainable mass spectrometry capabilities across QPS global laboratory facilities. In addition to replacing established analytical equipment, the upgrade encompasses instrument qualification, method transfer, workflow optimization, employee training, and long-term lifecycle management.

QPS Netherlands will introduce the new instruments through a controlled implementation and qualification process. Existing methods will be assessed and transferred using appropriate comparability, bridging, or validation activities, depending on their intended use and regulatory status. This approach is designed to maintain continuity for ongoing studies while establishing a renewed platform for future method development and validation.

“ICP-MS is an important part of our bioanalytical offering, particularly for programs requiring sensitive and selective quantification of elements in complex biological matrices,” said Fred van Heuveln, QPS Director, Bioanalysis. “By replacing both systems at the same time, we are creating an upgraded analytical platform that will ensure reliable project execution through efficient method deployment and sample analysis, while providing a platform for the evolving requirements of our clients.”

The two-system configuration will provide operational flexibility and redundancy. Standardizing the ICP-MS platform is expected to simplify training, maintenance, method transfer and routine laboratory support while helping QPS manage study schedules and changing analytical demands.

“This initiative represents more than an equipment replacement,” added Daniel Schulz-Jander, QPS Senior Director, Bioanalysis. “This strategic renewal of our ICP-MS systems ensures QPS maintains cutting-edge technology to deliver highly sensitive and robust analytical solutions for our clients' projects. This investment reinforces our ongoing commitment to providing exceptional elemental bioanalysis for both traditional and emerging drug development programs.”

QPS Netherlands has more than two decades of experience with ICP-MS-based bioanalysis. Its capabilities include total, free and trace elemental analysis, as well as LC-ICP-MS applications for speciation, stability and metabolite-related investigations. Installation, qualification, and phased implementation of the two NexION® 2200 systems are ongoing and scheduled to be completed in Q3 2026.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trial units, central laboratory services, PBMC processing, and clinical research operations services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com, email info@qps.com, or follow us on LinkedIn.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831322534/en/

Permalink

https://www.aetoswire.com/en/news/3108202656966

Contacts

QPS:

Name: Gabrielle Pastore

Phone: 1-302-635-4290

Email: Gabrielle.Pastore@QPS.com

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions

 LAS VEGAS - Monday, 31. August 2026 AETOSWire Print 

The Company recently completed an additional $5.0 million of common stock repurchases and $5.0 million of debt prepayment that brings total fiscal year-to-date capital return and balance sheet optimization to $30.9 million

(BUSINESS WIRE) -- Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026:

Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million.

Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million.

“Our year-to-date share repurchases and debt prepayments demonstrate our commitment to creating long-term stockholder value and our disciplined approach to capital allocation,” said Michael Perica, executive vice president and CFO, Rimini Street. “With $30.9 million already allocated to capital return and balance sheet optimization year-to-date in fiscal 2026, we have enhanced stockholder value, further reduced our debt and strengthened the balance sheet while preserving the financial flexibility to invest in our strategic growth priorities.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a proven, trusted global provider of end-to-end, mission-critical enterprise software support, managed services and innovative Agentic AI ERP solutions, and is the leading third-party support provider for Oracle, SAP and VMware software. The Company has signed thousands of IT service contracts with Fortune Global 100, Fortune 500, midmarket, public sector and government organizations who have leveraged the Rimini Smart Path™ methodology to achieve better operational outcomes, billions of US dollars in savings and fund AI and other innovation. To learn more, please visit www.riministreet.com, and connect with Rimini Street on X, Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “currently,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “outlook,” “plan,” “possible,” “goal,” “potential,” “predict,” “project,” “reflect,” “results,” “seem,” “seek,” “should,” “will,” “would” and other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to our ability to attract new clients or retain and/or sell additional products or services to existing clients; our ability to achieve and maintain an adequate rate of revenue growth; cost of revenue, including changes in costs associated with our efforts to grow and the results of any efforts to manage costs to align with current revenue expectations and the expansion of our offerings; the effects of increased intense competition in our industry and our ability to compete effectively; our ability to successfully educate the market regarding the advantages of our support and managed services for ERP software and to sell the products and services comprising our “Rimini Smart Path™” solutions portfolio, including but not limited to our Agentic AI ERP solutions; our intentions with respect to our pricing model and expectations of client savings relative to use of other providers; the evolution of the ERP software management and support landscape facing our clients and prospects; estimates of our total addressable market; the effects of seasonal trends on our results of operations, including the contract renewal cycles for vendor-supplied software support and managed services; the effects of the efforts of enterprise software vendors to sell upgrades or migrations to cloud-based versions of their enterprise software on our results of operations; our ability to scale our operations quickly enough to meet our clients’ changing needs or decrease our costs adequately in response to changing client demand; risks arising from incorporating artificial intelligence (“AI”) technologies into our products or services or any deficiencies associated with AI technologies used by us or by our third-party vendors and service providers; our ability to maintain, protect, and enhance our brand; the loss of one or more members of our management team and our ability to attract and retain additional qualified technical, sales and marketing personnel; our ability to expand our marketing and sales capabilities; our ability to avoid interruptions to, or degraded performance of, our services and the impact of any such interruptions or performance problems on our operations; our ability to defend against cybersecurity threats and to comply with data protection and privacy regulations; our expectations regarding new product offerings, innovation solutions, partnerships and alliance programs and our ability to develop and maintain strategic partnerships; our ability to expand internationally and the risks associated with global operations; our wind down of support services for Oracle’s PeopleSoft software products and the impact on future period revenue and costs incurred related to these efforts; the continuing impact of and our ability to comply with the terms of our July 2025 settlement agreement with Oracle; the impact of macro-economic trends, including inflation and changes in foreign exchange rates, as well as general financial, economic, regulatory and political conditions affecting the industry in which we operate and the industries in which our clients operate; our ability to generate significant capital through our operations or to raise additional capital necessary to fund and expand our operations and invest in new services and products; our business plan and our ability to effectively secure and manage our growth and associated investments; risks relating to retention rates, including our ability to accurately predict retention rates; our ability to protect our intellectual property; our ability to maintain an effective system of internal control over financial reporting; changes in laws or regulations, including tax laws or unfavorable outcomes of tax positions we take; tariff costs; our ability to realize benefits from our net operating losses; any negative impact of environmental, social and governance (“ESG”) matters on our reputation or business and the exposure of our business to additional costs or risks from our reporting on such matters; our credit facility’s ongoing debt service obligations and financial and operational covenants on our business and related interest rate risk; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; the volatility of our stock price; the amount and timing of repurchases, if any, under our stock repurchase program and our ability to enhance stockholder value through such program; our ability to maintain our good standing with the United States and international governments and capture new contracts with public sector entities; the occurrence of catastrophic events that may disrupt our business or that of our current and prospective clients; future acquisitions of, or investments in, complementary companies, products, subscriptions or technologies; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on July 30, 2026, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the U.S. Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2026 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831961587/en/

Permalink

https://www.aetoswire.com/en/news/3108202656965

Contacts

Investor Relations Contact

Dean Pohl

Rimini Street, Inc.

+1 925 523-7636

dpohl@riministreet.com

Media Relations Contact

Janet Ravin

Rimini Street, Inc.

+1 702 285-3532

pr@riministreet.com

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

 

SAN CARLOS, Calif. -

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA

ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial

 

(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study.

IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA and chemotherapy regimen, demonstrating an improved OS hazard ratio, continued durable outcomes, and a generally manageable safety profile. These results reinforce findings from IA1, in which the regimen met the progression-free survival (PFS) and OS endpoints, with the overall survival benefit observed across PD-L1 and HER2+ expression levels.

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne Medicines, said:

“Today’s results, coming just days after FDA approval of the HERIZON-GEA-01 regimens, add to a series of important milestones demonstrating their potential to transform the treatment of HER2-positive GEA. We now have compelling Phase 3 evidence of statistically significant and clinically meaningful overall survival results across both HERIZON-GEA experimental arms, reinforcing the opportunity to improve outcomes for patients beginning first-line treatment. This latest result is also particularly meaningful for BeOne given our rights to ZIIHERA across much of Asia, where the burden of gastroesophageal cancer is substantial, as we work to bring these treatment options to more patients around the world.”

Recent FDA approval establishes HERIZON-GEA-01 regimen as potential new standard of care

On August 25 2026, the U.S. Food and Drug Administration (FDA) approved supplemental Biologics License Applications (sBLAs) for both ZIIHERA and TEVIMBRA in combination with chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma, making it the first FDA-approved immunotherapy-based regimen in this setting to demonstrate median OS exceeding two years, regardless of PD-L1 status. The approval was based on results from IA1 of HERIZON-GEA-01, which were published in The New England Journal of Medicine earlier this year.

The safety profile of ZIIHERA plus chemotherapy and TEVIMBRA plus ZIIHERA and chemotherapy at IA2 was generally consistent with that of IA1 and the known safety profiles of the individual treatment components, with no new safety signals identified.

The results from IA2 have been submitted for presentation at a major medical meeting in the fourth quarter of 2026.

About the HERIZON-GEA-01 Phase 3 Trial

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with Jazz Pharmaceuticals, to evaluate and compare the efficacy and safety of ZIIHERA plus chemotherapy, with and without TEVIMBRA, to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries. Patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: ZIIHERA in combination with chemotherapy and TEVIMBRA; ZIIHERA in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial evaluated dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

About ZIIHERA (zanidatamab-hrii)

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.1

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

ZIIHERA is a registered trademark of Zymeworks BC Inc.

About TEVIMBRA (tislelizumab-jsgr)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

TEVIMBRA is the cornerstone of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved for various solid tumors (see prescribing information) in over 50 countries, and more than 2 million patients have been treated globally.

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and Precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

The most common adverse reactions (≥20%), including lab abnormalities, in patients receiving TEVIMBRA + zanidatamab + chemotherapy were diarrhea, nausea, anemia, decreased appetite, vomiting, hypokalemia, fatigue, rash, decreased neutrophil count, decreased platelet count, peripheral neuropathy, infusion-related reaction, and increased AST.

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including the potential of the HERIZON-GEA-01 regimens to transform the treatment of HER2-positive GEA; the presentation of results from IA2 at a future medical meeting; the potential of TEVIMBRA across multiple tumor types and disease settings; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

1 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260831944229/en/

Permalink

https://aetoswire.com/en/news/3108202656960

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com

 

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology

 TOKYO - Friday, 28. August 2026 AETOSWire  

(BUSINESS WIRE) -- Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements.

As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray metrology technology is essential for high-precision, non-destructive analysis needed for supporting stable mass production, yet conventional techniques are reaching their limits in areas such as evaluation of microstructures and accurate structural analysis in the depth direction. Addressing these challenges requires new metrology technologies, including soft X-rays (X-rays with longer wavelengths and lower energy than conventional X-rays), as well as stronger capabilities built in collaboration with synchrotron radiation facilities.

In addition, fostering professionals who can systematically understand advanced X-ray metrology and apply it in both industry and research has become increasingly important.

To address these two challenges of technology and human resources, Tohoku University, home to the next-generation synchrotron radiation facility NanoTerasu and a leader in information science, and Rigaku, with its expertise and a proven track record in X-ray metrology, have established a new institute. Under the banner “Beyond The Limits,” the Institute will integrate technological innovation and talent development to push beyond the current limits of X-ray metrology.

The Institute seeks to focus on three key goals:

1. Advancement of X-ray Metrology Technology

The Institute will develop microstructure metrology technologies by leveraging NanoTerasu’s strengths in the soft X-ray field, integrating Tohoku University’s expertise in information science with Rigaku’s technical know-how to advance data analysis. It aims to establish a technological foundation that meets increasingly sophisticated metrology and analysis needs.

2. Promotion of Collaborative Research

The Institute will pursue collaborative research across a broad range of fields that require X-ray metrology, including challenges that cannot be addressed with conventional technologies.

3. Training and Support for Next-Generation Researchers and Engineers

The Institute will provide systematic education in X-ray metrology technology, from its fundamentals to its applications to new materials and structures, with the aim of introducing credit-bearing courses. It aims to cultivate researchers and engineers who can contribute to both industry and academia. In addition, the Rigaku Scholarship System will provide scholarships to graduate students conducting X-ray-related research, supporting their academic research toward a degree thesis as well as its application to practical metrology technologies.

During its initial three-year term, the Institute will focus on achieving the goals of its joint research plan. Priority will be given to the practical application of soft X-ray metrology for semiconductors and the advancement of data analysis technologies through information science. Building on these achievements, the Institute will expand its research to broader fields, including electronic and functional materials, where precise characterization of microstructures and material states is essential.

By cultivating researchers and engineers with the skills to contribute to both industry and academia, the Institute aims to foster a cycle of knowledge exchange in X-ray metrology and help establish a sustainable foundation for innovation.

“The driving force behind Rigaku’s growth has been our ability to provide optimal solutions using X-ray technology whenever new metrology targets have emerged,” says Kazuhiko Omote, General Manager, X-ray Research Laboratory, Rigaku Corporation (Chief Operations Officer and Specially Appointed Professor, the Institute) “Although more than 130 years have passed since their discovery and the fundamental principles of X-rays appear to have been fully elucidated, I am convinced that X-rays still hold numerous possibilities that have yet to be revealed. Unlocking these possibilities will require the contributions of the next generation. At the Institute, we aim to explore uncharted territory in collaboration with Tohoku University’s academic expertise, while nurturing the next generation of talent to take on these challenges.”

“X-ray metrology is a fundamental technology that supports a wide range of fields, including semiconductors, materials, and life sciences,” says Daichi Chiba, Director, International Center for Synchrotron Radiation Innovation Smart, Tohoku University (Operations Support Officer, the Institute). “Continued innovation is essential to unlock its full potential. The Institute aims not only to serve as a platform connecting Rigaku’s advanced technical capabilities with Tohoku University’s research infrastructure, including NanoTerasu, but also to create an environment where diverse ideas inspire one another across disciplines, generations, and industry-academia boundaries, generating new ideas and technologies. True to its name, “Beyond The Limits,” we hope to break free from existing frameworks and, together with the next generation of researchers and engineers, shape the future of X-ray metrology technology. We hope this Institute will become a launchpad for innovation that pushes beyond today’s technological limits.”

Overview of the Co-Creation Research Institute

Name: Rigaku–Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits

 

Activities: Advancing X-ray metrology, developing new metrology methods, and fostering the next generation of researchers

 

Management Structure:

(1) Chief Operations Officer and Specially Appointed Professor:

Kazuhiko Omote

General Manager, X-ray Research Laboratory, Rigaku Corporation

(2) Operations Support Officer:

Daichi Chiba

Director, International Center for Synchrotron Radiation Innovation Smart, Tohoku University

Professor, Nano Materials Function Creation Smart lab

 

Location: Tohoku University

 

Period of Operation: August 1, 2026 – July 31, 2029

The period may be extended based on the outcomes achieved.

About the Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in 136 countries and regions and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”

For details, please visit: rigaku-holdings.com/english

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260828688510/en/

Permalink

https://www.aetoswire.com/en/news/2808202656945

Contacts

Press Contact:

Sawa Himeno

Director, Communications Dept., Rigaku Holdings Corporation

prad@rigaku.co.jp　

New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 2026

 Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction

 

Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year's edition of the exhibition.

This forms part of the largest auction programme in the exhibition's history, held under the theme "A Legacy of Pride", organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers' Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September.

The falcon, owned by Mark Moglich Falcon Farm in the United States, stands out for its rare pure white colouring and exceptional physical characteristics. Weighing 1,000 grams and measuring 16.5 inches in both length and width, the Qarmousha Pure Ultra White attracted considerable attention from leading falconers and bidders.

Humaid Matar Al Dhaheri, Group CEO of ADNEC Group, said: “The exceptional calibre of the falcons participating in these auctions reflects the global standing they have achieved through the Abu Dhabi International Hunting and Equestrian Exhibition. We remain committed to providing a platform that brings together the finest falcons and bloodlines from around the world. These auctions also play an important role in preserving breed quality and sustainability while reinforcing Abu Dhabi’s position as a leading international destination for falconry and its authentic traditions, supporting efforts to safeguard this treasured Emirati heritage for future generations.”

This year’s edition features 55 leading local and international falcon breeding and care farms, representing a 20% increase compared with last year. Among them are nine first-time participants, highlighting the growing stature of the auctions and their increasing appeal among breeders and falconers worldwide.

Permalink

https://www.aetoswire.com/en/news/3008200656950

Contacts

Salam Shehady 

ADNEC@APCOWORLDWIDE.COM

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

 MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)

MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve Fatigue

Approval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32

 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer.

MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1

“For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Current treatments, such as phlebotomy, leave a significant gap for too many patients and can pose challenges to daily life and routines. The approval of MIMRYLO offers clinicians and patients a novel, first-in-class therapy that targets erythrocytosis, which drives excess red blood cell production in PV. The strength and consistency of the VERIFY data give me real confidence in MIMRYLO’s potential to advance how we treat PV in everyday practice and to maintain hematocrit control.”

Uncontrolled Hematocrit is a Challenge in the Treatment of PV

Affecting approximately 90,000 people in the U.S., PV is characterized by the overproduction of red blood cells (erythrocytosis), leading to elevated hematocrit which can increase blood viscosity, or thickness.2,3 This has the potential to result in life-threatening thrombotic events, including stroke, deep vein thrombosis and pulmonary embolism.4 Maintaining hematocrit levels consistently below 45% can prevent thrombotic events and alleviate burdensome symptoms, including severe fatigue, pruritus (itching), difficulty concentrating and night sweats.4 An estimated 78% of patients still experience uncontrolled hematocrit with current standard of care, including phlebotomy and cytoreductive therapies.5 Patients with PV experiencing uncontrolled hematocrit have a four times higher risk of cardiovascular death or major cardiovascular events.4

“People living with PV often experience complex and invisible symptoms, from extreme fatigue to the emotional strain of living with a chronic blood cancer,” said Kapila Viges, Chief Executive Officer, MPN Research Foundation. “At the same time, we know that every patient’s experience with PV is different, underscoring the need to continue to listen closely to the community to understand what matters most. There remains a need for treatments that better address these daily challenges. This meaningful approval reflects important progress and brings forward a new treatment option in a disease where patients have long needed innovation and more choices. We are encouraged by MIMRYLO’s potential to help patients meet their treatment goals.”

MIMRYLO is a First-In-Class Treatment Option for Adults with PV

The approval was supported by data from the global randomized Phase 3 VERIFY study (NCT05210790) that included 293 patients with PV, showing that MIMRYLO met all efficacy endpoints and demonstrated a favorable safety profile. In the study, patients receiving MIMRYLO plus current standard of care demonstrated a higher response rate compared to placebo plus current standard of care. This included hematocrit control, a reduction in the need for phlebotomy and improvement in fatigue as measured by PROMIS Fatigue Short Form 8a.

MIMRYLO was generally well-tolerated through 52 weeks of treatment in the VERIFY trial. The most common treatment-emergent adverse events in MIMRYLO-treated patients were injection site reactions and anemia. Learn more about the Phase 3 data results here.

“The approval of MIMRYLO underscores the strength of Takeda’s late-stage pipeline and our focus on developing genuinely differentiated therapies for patients who are urgently waiting for new options,” said Julie Kim, President and Chief Executive Officer, Takeda. “We are at an important inflection point as we prepare to deliver three new medicines, which have the potential to drive our future growth and are a reflection of our commitment to advancing innovation that doesn’t just add to the treatment landscape, but reshapes it. We are grateful to the patients, care partners, advocates and investigators who helped make this approval possible.”

The open-label extension of the VERIFY trial is ongoing and Takeda will share further findings at upcoming medical conferences. Takeda is working with regulators outside of the U.S. to potentially bring MIMRYLO to more patients worldwide.

This approval does not result in any changes to Takeda’s consolidated financial forecast for the fiscal year ending March 31, 2027 (FY2026).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

New or Worsening Thrombocytosis: MIMRYLO may increase platelet counts in patients with PV. Platelet counts generally plateaued on treatment by Week 8. After initiating MIMRYLO and during dose modifications, monitor CBC every 2 to 4 weeks or as clinically indicated. Platelet elevations associated with MIMRYLO may require cytoreductive therapy initiation, modification, or MIMRYLO dose modifications or discontinuation.

Injection-Site Reactions: Injection site reactions (including Grade 3 reactions) have been reported in patients treated with MIMRYLO. The most common injection site reactions reported were erythema, pruritus, pain, and swelling. Use ice, topical corticosteroid creams, antihistamines or analgesics, as needed, to treat injection site pain and swelling.

Embryo-Fetal Toxicity: Based on findings from animal reproduction studies, MIMRYLO may cause fetal harm when administered to a pregnant woman. Advise patients to stop taking MIMRYLO if they become pregnant.

ADVERSE REACTIONS

The most common (>15%) adverse reactions were injection site reactions (56%) and anemia (16%).

USE IN SPECIFIC POPULATIONS

Lactation: Because of the potential for serious adverse reactions in the breastfed child, including impaired iron absorption, advise patients not to breastfeed during treatment with MIMRYLO and for 30 days after the final treatment.

Females and Males of Reproductive Potential

Pregnancy Testing: Prior to initiating MIMRYLO, pregnancy testing is recommended for females of reproductive potential.

Contraception: Advise female patients of reproductive potential to use effective contraception during treatment with MIMRYLO and for at least 30 days after the final dose of MIMRYLO.

To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-844-662-8532 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see MIMRYLO (rusfertide) full Prescribing Information.

About MIMRYLO™

MIMRYLO™ is a first-in-class subcutaneous treatment that mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and erythrocytosis. By targeting the underlying mechanism of iron dysregulation in polycythemia vera, MIMRYLO aims to reduce excess red blood cell production and help patients maintain hematocrit control. MIMRYLO is administered once weekly via subcutaneous injection and has been generally well-tolerated in clinical trials to date. Protagonist discovered MIMRYLO and led its development through Phase 3. Takeda now has exclusive global development and commercialization rights for MIMRYLO.

About VERIFY

The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating MIMRYLO in 293 patients with polycythemia vera over a 156-week period, with treatment extension for participants who are continuing to derive benefit from MIMRYLO beyond the 156-week treatment period. The study is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered MIMRYLO in patients with uncontrolled hematocrit who are phlebotomy-dependent despite current standard of care treatment, which could include phlebotomy, hydroxyurea, interferon and/or ruxolitinib.

The primary endpoint of the study was the proportion of patients achieving a response during Weeks 20-32, which was defined as the absence of “phlebotomy eligibility.” To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%. Key secondary endpoints evaluated at Week 32 included mean number of phlebotomies, proportion of patients maintaining hematocrit <45%, mean change in fatigue score as measured by PROMIS Fatigue Short Form 8a and total symptom burden as measured by Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0.

All patients have completed their participation in the randomized, placebo-controlled portion of the study evaluating the efficacy and safety of MIMRYLO plus current standard of care versus placebo plus current standard of care and are now in the open-label portions of the study.

About Polycythemia Vera (PV)

Polycythemia vera (PV) is a chronic blood cancer characterized by the overproduction of red blood cells (erythrocytosis), which increases blood viscosity, or thickness, and can result in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism. Hematocrit is the ratio of red blood cells to the total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of less than 45% is the primary treatment goal in PV to prevent thrombotic events and alleviate burdensome symptoms, including severe fatigue, difficulty in concentrating, night sweats and pruritus.

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Takeda Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Takeda Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

*Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

References

Barbui T, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018; 32(5), 1057-1069.

Vachhani PJ. Estimated prevalence of polycythemia vera in the United States (2025-2030): SEER analysis with modeled reporting delay. J Clin Oncol. 2026;44(suppl 16):e18589.

Lu X, Chang R. Polycythemia Vera. [Updated 2023 Apr 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557660/

Marchioli R, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.

VVerstovsek S, et al. Real-world treatments and thrombotic events in polycythemia vera patients in the USA. Ann Hematol 2023;102:571-581.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824773270/en/

Permalink

https://www.aetoswire.com/en/news/2908202656949

Contacts

Investor Relations

Christopher O’Reilly

takeda.ir.contact@takeda.com

Japanese Media

Tsuyoshi Tada

toiawase_kouhou@takeda.co.jp

U.S. and International Media

Lauren Sherman

lauren.leedberg@takeda.com